Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00006203 · ClinicalTrials.gov registry record · Phase 4

Naltrexone, Craving, and Drinking

A Phase 4 study of Alcoholism, sponsored by Brown University.

Completed
Registry status
Phase 4
Development phase
180
Enrollment target
1
Study location

NCT00006203 is a Phase 4 study of Alcoholism that has completed, run by Brown University. The registered enrollment target is 180 participants, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00006203, a Phase 4 study of Alcoholism, has completed, sponsored by Brown University.

COMPLETED
Registry status
Phase 4
Development phase
180 participants
Enrollment target
1
Study location

Study Summary

This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions. Participants will monitor and record their daily desires to drink, environmental circumstances in which urges occur, and drinking behavior using a palm top computer. Participants will receive naltrexone or a placebo. One week after receiving medication, all participants will be asked to respond to alcohol-related cues that may or may not arouse the desire to drink.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Naltrexone 50 Mg

Study Locations (1)

Rhode Island

  • Center for Alcohol and Addiction Studies, Brown University - Providence

Trial Details

FieldValue
Enrollment Target 180 participants
Est. Completion 2005-05
Phase Phase 4

Sponsor

Brown University

231 total trials

What the Registry Record Tells You About NCT00006203

The ClinicalTrials.gov registry entry for NCT00006203 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 372-participant average among 65 other Alcoholism trials with a reported enrollment target (52% lower). The listed sponsor is Brown University, which has 231 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Alcoholism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00006203 reports 1 study location spanning 1 distinct geographic area - top geographies include Rhode Island.

Frequently Asked Questions

What is clinical trial NCT00006203 about?

NCT00006203 is a clinical study titled "Naltrexone, Craving, and Drinking". This 5-week study will examine the effects of naltrexone on alcohol craving, drinking rates, and reaction to drinking-related triggers, or cues, in participants' everyday environment and in laboratory sessions. Participants will monitor and record their daily desires to drink, environmental circumst...

What is the current status of trial NCT00006203?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 180 participants. Estimated completion is 2005-05.

What conditions does trial NCT00006203 study?

This clinical trial studies the following conditions: Alcoholism.

What interventions are being tested in trial NCT00006203?

The interventions under investigation include: Placebo (DRUG), Naltrexone 50 Mg (DRUG).

Who is sponsoring clinical trial NCT00006203?

This trial is sponsored by Brown University, which has 231 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00006203 being conducted?

This trial has 1 study location across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alcoholism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.